STATE-OF-THE-ART PAPER
Defining the Role of Basal and Prandial Insulin for Optimal Glycemic Control
Edward S. Horton, MD*
Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts
Manuscript received April 7, 2008;
revised manuscript received November 4, 2008,
accepted November 6, 2008.
* Reprint requests and correspondence: Dr. Edward S. Horton, Joslin Diabetes Center, One Joslin Place, Boston, Massachusetts 02215 (Email: edward.horton{at}joslin.harvard.edu).
Type 2 diabetes mellitus is a progressive disease characterized by early impairment of beta-cell function and ultimately loss of beta-cell mass. Hence, a single daily injection of a long-acting insulin is commonly initiated after intensification of oral antihyperglycemic therapy. Hemoglobin A1C should be measured every 3 months and therapy adjusted if the target is not met. As beta-cell function continues to decline, it is often necessary to add exogenous bolus insulin therapy, using short-acting insulin analogs or regular insulin. Alternatively, the use of pre-mixed insulin preparations, combining both long-acting and short-acting insulins, may be used.
Key Words: diabetes hemoglobin A1C hyperglycemia insulin
|
Abbreviations and Acronyms
| | A1C = hemoglobin A1C | | CI = confidence interval | | CV = cardiovascular | | HR = hazard ratio | | MI = myocardial infarction | | OAD = oral antihyperglycemic drug | | T2DM = type 2 diabetes mellitus | | TZD = thiazolidinedione |
|
This article has been cited by other articles:

|
 |

|
 |
 
C. J. Pepine
Insulin as a cardiovascular therapeutic: improving glycemic control in patients with coronary artery disease.
J. Am. Coll. Cardiol.,
February 3, 2009;
53(5 Suppl):
S1 - S2.
[Full Text]
[PDF]
|
 |
|
|